Changjiang Securities Company Limited(000783) underwriting sponsor Co., Ltd
About Jiangxi Fushine Pharmaceutical Co.Ltd(300497) change part to specific pair
Like the purpose of raising funds by issuing shares and the verification meaning of new raised investment projects
see
Changjiang Securities Company Limited(000783) underwriting recommendation Co., Ltd. (hereinafter referred to as “Changjiang recommendation”) as Jiangxi Jiangxi Fushine Pharmaceutical Co.Ltd(300497) shares
A recommendation institution under the continuous supervision of a limited company (hereinafter referred to as ” Jiangxi Fushine Pharmaceutical Co.Ltd(300497) ” or “the company”) according to the
Measures for the administration of securities issuance and listing recommendation business, Shenzhen Stock Exchange gem stock listing rules, Shenzhen Stock Exchange
The Jiangxi Fushine Pharmaceutical Co.Ltd(300497) change department
The purpose of the funds raised by issuing shares to specific objects and the new projects raised and invested have been verified
The situation and opinions are as follows:
1、 Basic information of raising funds by issuing shares to specific objects
With the approval of Jiangxi Securities Regulatory Commission issued by China Securities Regulatory Commission (zjxk [2020] No. 3231)
The official reply on the registration of shares issued by Jiangxi Fushine Pharmaceutical Co.Ltd(300497) Co., Ltd. to specific objects agrees to register, and the company
79191640 ordinary shares (A shares) are issued by the target, with a par value of RMB 1.00 per share and an issue price of 12.68
Yuan / share, with a total raised capital of 1004149995.20 yuan, deducting the recommendation, underwriting and issuance expenses of RMB
10000000.00 yuan, less other external expenses directly related to the issuance of equity securities 2785933.52
The actual net amount of raised funds is RMB 991364061.67. The above raised funds will be released in December 2020
In place on January 31, it was verified by Lixin Certified Public Accountants (special general partnership) and issued a letter of consultation
The capital verification report (BZ [2021] No. zf10008) has been deposited in the special account for raised funds.
2、 Original project plan and actual investment
As of December 31, 2021, this issue of shares to specific objects to raise funds for investment projects and
The usage is as follows:
Unit: 10000 yuan
Project name of the main project for the implementation of the raising sequence of the raised funds not used by the raised funds expected investment to be invested net raised funds to be invested cumulative implementation progress total amount of raised funds No. investment amount (including interest income)
Jingdezhen Fu
1. Fuxiang biomedicine 105382.0089000.0087721.4132912.83 under construction 55351.29 Technology Co., Ltd
department
Weifang Aotong has an annual output of 616 tons, which is 62.3721 million yuan
2 Pharmaceutical Co., Ltd. Wei intermediate, 90015000.0011415.0011415.00 (including 5321.78 tons of Batan intermediate signed and put into operation, and the same unpaid
Project equipment (balance)
Total 120382.00100415.0099136.4139150.04-60673.07
3、 Reasons for changing the purpose of raised funds of some convertible bonds and adding raised investment projects
Since its establishment, the company has been continuously improving and developing around the industrial chain, adhering to the “pharmaceutical intermediates – raw materials”
“Drug preparation” development strategy. While consolidating its main business, the company actively relies on years of experience in the pharmaceutical industry
Formed quality management and EHS management ability, solid process development and high standard large-scale production and manufacturing ability
To continuously track the development trends of the market and industry, so as to seek new opportunities in line with the company’s strategic development.
On the premise of comprehensively considering the company’s overall development strategy and capacity layout, in order to ensure that the raised funds can be obtained as soon as possible
In order to improve the investment efficiency, improve the use efficiency of raised funds and grasp the opportunity of product development, the company plans to distribute to specific objects
Part of the raised funds of the bank’s stock raising investment project “Fuxiang biomedical project” is 239057200 yuan and used to
Savings from the “616 T / a navir intermediate and 900 t / a Batan intermediate project” of the fixed object’s stock issuance and investment project
The raised fund is 53.2178 million yuan, totaling 29.2275 million yuan, for the construction of “10000 tons of VC and 2000 tons per year”
Ton FEC project “to ensure the medium and long-term sustainable and stable development of the company.
The investment projects of raised funds after this change are as follows:
Unit: 10000 yuan
Raised funds
No. name of implementing entity project estimated total planned investment amount
Amount (including interest)
(amount)
1. Fuxiang biomedical project of Jingdezhen Fuxiang life science 105382.0064358.40
Technology Co., Ltd
The project has been completed
2 Weifang Aotong Pharmaceutical Co., Ltd. has an annual output of 616 tons of navir intermediates and 900 tons of 15000.00, which has been put into operation
Raised funds for Batan intermediate project of the company
62.3721 million yuan
3. Jingdezhen Fuxiang life department has an annual output of 10000 tons of VC and 2000 tons of fec32227.5029227.50
Technology Co., Ltd. project
Total 99823.11
If the funds raised for the above projects are insufficient, the company shall construct according to the original project with its own funds and self raised funds
It is planned to continue the construction.
4、 Description of new raised investment projects
(i) Basic information and investment plan of the project
1. Project Name: 10000 t / a VC and 2000 t / a FEC project
2. Project implementation subject: Jingdezhen Fuxiang Life Technology Co., Ltd
3. Project implementation location: Jingdezhen high tech Zone, Jiangxi Province (south of Jingdezhen Power Plant)
4. Project construction period: 12 months
5. Project investment amount: the total investment is 322.275 million yuan, including construction investment of 292.275 million yuan and initial working capital of 30 million yuan.
6. Source of funds: part of the raised funds and balance raised funds changed this time
7. Project construction content: new production workshop, utility building, warehouse, comprehensive auxiliary building, regional control room, tank farm, plant general layout and plant comprehensive pipeline, etc.
（2） Basic information of project implementation subject
1. Project unit: Jingdezhen Fuxiang Life Technology Co., Ltd
2. Legal representative: Bao Jianhua
3. Registered capital: 100 million yuan only
4. Business term: long term
5. Business scope: general items: biomedical technology development, technical consultation, technology transfer, technical services: Manufacture and sales of tablets, injections and APIs (operated with drug production and operation license): Manufacture and sales of pharmaceutical intermediates and chemical raw materials (excluding hazardous chemicals); Operate import and export business (in addition to licensing business, it can independently operate projects not prohibited or restricted by laws and regulations).
6. Shareholders: Jiangxi Fushine Pharmaceutical Co.Ltd(300497) , holding 100%
7. Financial status: Jingdezhen Fuxiang was established in April 2020. At present, it is in the construction period and has not yet carried out business.
（3） Project feasibility analysis
1. Project construction background and feasibility
(1) Broad market prospects
In the first half of 2021, led by the goal of “carbon peak and carbon neutralization”, the national lithium-ion battery industry achieved rapid growth, continuously improved product quality and process technology, and the overall development trend of the industry was good. The new energy vehicle industry development plan (2021-2035) specifies that by 2025, the sales of new energy vehicles will reach about 20% of the total sales of new vehicles. Many provinces and cities in China have made new material industry plans in line with their own regional development, and the industry has ushered in a new stage of development. According to the data of China Automobile Industry Association, the cumulative sales volume of Shanxi Guoxin Energy Corporation Limited(600617) passenger cars in the first half of 2021 was 1.206 million, a year-on-year increase of 201.5%. With the huge market demand and good development prospect of new energy vehicles and lithium-ion battery industry, the market demand of vinyl carbonate (VC), fluorovinyl carbonate (FEC) and other products will increase simultaneously, and the industrial development prospect is broad. (2) In line with national policy direction
As the key materials of lithium battery, CEC (vinyl chloride carbonate), VC (ethylene carbonate) and FEC (vinyl fluoride carbonate) are one of the most front-end basic materials in the lithium new energy industry chain. Their production process can fully realize the resource utilization of waste heat of power plant, and industrial waste salt can be recycled and comprehensively utilized by using advanced technology and equipment. Therefore, the project complies with the national 14th five year plan, the 14th five year plan for circular economy development, the 14th five year plan of Jiangxi Province and relevant industrial policies, and belongs to the encouraged projects in the Guiding Catalogue for industrial structure adjustment (2019 version).
(3) The company has a good foundation for project implementation
Since its establishment, the company has always attached importance to the innovation of product production technology and the improvement and optimization of process. Focusing on the core processes such as green substitution of reactants, optimization of reaction process, simplification of reaction operation and fine control of reaction conditions, after years of continuous exploration, R & D and repeated experiments, the company has developed large tonnage one pot production technology, catalytic oxidation reaction technology, chiral synthesis technology Cleaner production technology and other technical processes have effectively overcome the shortcomings of traditional technologies and processes. Therefore, the company has rich chemical synthesis technology advantages and industry experience. At present, the company has established the core team of the project, and the relevant preparations for the early construction of the project are advancing in an orderly manner. Based on the company’s efficient implementation ability in the promotion of past projects and the market sales ability formed over the years. Once the relevant administrative procedures of the project are completed, the company can quickly promote the project construction according to the project plan, so as to put the project into operation as soon as possible.
(4) The needs of the company’s strategic development planning
The company has always focused on the R & D, production and sales of high-end antibiotic APIs and intermediates and antiviral drug intermediates, adhered to the integrated development strategy of “pharmaceutical intermediates – APIs – preparations”, and achieved good results. Considering the uncertain impact of the epidemic situation and relevant national policies, the company combines its own advantageous resources and complies with the industrial development trend
